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Abstract
Background: Pemphigus vulgaris (PV) is an acquired autoimmune blistering disorder in which
greater than 80% of active patients produce autoantibodies to the desmosomal protein desmogelin
3 (Dsg3). As the disease progresses, 40–50% of patients may also develop reactivity to a second
component of the desmosomal complex, desmogelin 1 (Dsg1). T cells are clearly required for the
production of autoantibodies in PV. However, few T-cell specificities within Dsg3 or Dsg1 have
been reported to date, and the precise role of T-cells in disease pathogenesis and evolution remains
poorly understood. In particular, no studies have addressed the immunological mechanisms that
underlie the observed clinical heterogeneity in pemphigus. We report here a structure-based
technique for the screening of DRB1*0402-specific immunological (T-cell epitope) hotspots in both
Dsg3 and Dsg1 glycoproteins.
Results: High predictivity was obtained for DRB1*0402 (r2 = 0.90, s = 1.20 kJ/mol, q2 = 0.82, spress
= 1.61 kJ/mol) predictive model, compared to experimental data. In silico mapping of the T-cell
epitope repertoires in Dsg3 and Dsg1 glycoproteins revealed that the potential immunological
hotspots of both target autoantigens are highly conserved, despite limited sequence identity (54%
identical, 72% similar). A similar number of well-conserved (18%) high-affinity binders were
predicted to exist within both Dsg3 and Dsg1, with analogous distribution of binding registers.
Conclusion: This study provides interesting new insights into the possible mechanism for PV
disease progression. Our data suggests that the potential T-cell epitope repertoires encoded in
Dsg1 and Dsg3 is substantially overlapping, and it may be possible to apply a common, antigen-
specific therapeutic strategy with efficacy across distinct clinical phases of disease.
Background
Pemphigus vulgaris (PV) is characterized by the loss of
normal epithelial cell-to-cell adhesion leading to blister-
ing which may involve the mucous membranes, non-
mucosal cutaneous surfaces, or both [1]. Pemphigus
autoantibodies (autoAb) are mainly directed against the
desmosomal glycoproteins desmoglein 3 (Dsg3) and des-
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moglein 1 (Dsg1), members of the cadherin superfamily
of cell adhesion molecules [2].
Clinical evolution of disease expression is common in PV
[3,4]. In early disease, a majority of PV patients develop
autoantibodies to Dsg3 coincident with mucosal blisters.
In later stages, significant proportions of patients develop
additional lesions on non-mucosal cutaneous sites and
exhibit non-cross-reactive immunity to both Dsg3 and
Dsg1 [5].
Two immunologic phenomenon termed "antigen mim-
icry" [5] and "epitope spreading" [5-8] have been pro-
posed as possible pathogenic mechanisms responsible for
the shift in autoreactive lymphocyte (T- or B-cell) profile
from Dsg3+/Dsg1- to Dsg3+/Dsg1+. Antigen mimicry can
be defined as the generation of lymphocyte (T- or B-cell)
reactivity towards a protein due to its close structural sim-
ilarity to unique exogenous antigens, or new determinants
that have been generated endogenously [5]. Epitope
spreading in the context of autoimmunity refers to the
development of epitope-specific immune responses that
are distinct from and non-cross-reactive with disease-
inducing epitopes on the same (or different) protein sec-
ondary to the release of such a self-protein during an
autoimmune response [8-10].
A close relationship between antigen mimicry and epitope
spreading exists, with epitope spreading usually occurring
after an initial episode of antigen mimicry [5]. Exogenous
and endogenous antigens that may trigger cross-reactivity
with self-proteins have not yet been defined in pemphigus
[5]. While the modulation of autoantibody reactivities in
the transformation of one disease subform into another
has been actively explored [3-7], the role of T-cells under-
lying the evolution of autoreactive processes and epitope
spreading remains poorly understood. To date, limited
studies on T-cell specificities within PV have been
reported [11-20]. The reported HLA associations with dis-
ease may serve to provide the genetic link that drives the
evolving autoimmune responses in pemphigus. PV is
known to be strongly associated with the HLA-DR allele
DRB1*0402 [21-26]; it is present in more than 90% of
Ashkenazi patients [27]. The DRB1*0402 allele is also
common in other ethic backgrounds, including patients
from France [28], Italy [29], Spain [30], Argentina [31]
and Iran [32].
We have previously investigated the docking potentials of
Dsg3 peptides to DRB1*0402 using a hybrid approach
that integrates the strength of Monte Carlo simulations
and homology modeling [33-37]. Consistent with experi-
mental evidence [11], computational simulations reveal
that a potentially large number of T-cell epitopes may be
relevant in the pathogenesis of PV [33]. In the current
study, we have extended our analysis to the Dsg1 glyco-
protein and applied a new scoring scheme for identifica-
tion of immunological (T-cell epitope) hotspots within
both Dsg3 and Dsg1 self-antigens. In silico mapping of the
T-cell epitope repertoires within Dsg3 and Dsg1 suggests
that similar peptides from both PV target antigens may be
involved in disease progression and the evolution in auto-
reactive lymphocyte reactivity during the course of disease
from one clinical subtype to another (mucosal PV to
mucocutaneous PV).
Results and Discussion
Comparison of Dsg1 and Dsg3 Extracellular Domains
The Dsg3 extracellular domain (ECD) has an extensive
surface area of 32133 Å 2. This surface area is ~3% larger
than the Dsg1 ECD atomic accessible surface (31093 Å 2).
The general folds of Dsg1 and Dsg3 ECDs are similar (Fig-
ures 1 and 2). In particular, the ECD1, ECD2 and ECD3 of
Dsg1 and Dsg3 are well conserved with Cα r.m.s.d. of 1.03
Å, 1.09 Å and 1.94 Å, respectively. The main differences
between Dsg1 and Dsg3 ECDs lie in ECD4 (Cα r.m.s.d. =
3.76 Å) and ECD5 (Cα r.m.s.d. = 6.95 Å). In ECD4, the
most obvious difference between the structures involve
the loop 411–420 of Dsg1 and loop 405–422 of Dsg3.
The backbone of Gln410, Ala411 and Ile412 in Dsg1 are
intercalated more deeply into the ECD4 interface than the
corresponding residues in Dsg3. In ECD5, the loop 468–
479 curled upward toward Dsg1, with differences of up to
2.18 Å between the corresponding positions in Dsg3
(loop 468–475). It appears that these regions may not
contain high concentration of T-cell epitopes and do not
contribute directly to the differences in T-cell specificities
of the two PV target antigens (Figure 3). Nonetheless,
these structural differences are solvent exposed and may
interact with pemphigus autoAb.
Dsg1 and Dsg3 Share Common Immunological Hotspots
The locations of Dsg1 and Dsg3 immunological hotspots
are highly conserved across the ECD, TM and intracellular
domain (ICD), despite limited sequence identity (54%
identical, 72% similar). There are substantial overlaps
between predicted and known immunological (T-cell
epitope) hotspots (Dsg3 145–192, Dsg3 240–303, Dsg3
570–614) at the threshold -123 kJ/mol (Figure 2). At this
threshold, the number of predicted Dsg3 hotspots are ten
(residues 21–88, 125–147, 173–221, 245–299, 330–391,
435–456, 495–522, 584–640, 772–797, 830–859).
Among these, one spans the signal peptide (SP), propep-
tide (PP) and the ECD; six are present in the ECD; one
extends across the ECD, TM and ICD; while two hotspots
are predicted to exist in the ICD (Figure 2). Similarly, nine
hotspots were predicted for Dsg1 (residues 1–62, 82–151,
173–240, 310–372, 423–455, 470–498, 550–569, 656–
688, 732–760), all of which overlap with those from Dsg3
(Figure 2). Collectively, these results suggest that theBMC Immunology 2008, 9:30 http://www.biomedcentral.com/1471-2172/9/30
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potential T-cell epitope repertoire encoded in Dsg1 and
Dsg3 is substantially overlapping, and may help to
explain the molecular basis underlying the observed inter-
molecular spreading from Dsg3 to Dsg1 targets during the
course of PV.
Effects of Binding Registers in Peptide Selection
We investigated the effect of multiple contact regions or
binding registers in Dsg3 peptides specific to DRB1*0402
[33]. Among 985 Dsg3 peptide sequences (including SP
and PP derived sequences), 658 were predicted high-affin-
ity binders with 77% containing two or more registers that
can be docked into the binding groove of DRB1*0402. A
similar number of high-affinity binders are predicted to
exist within the Dsg1 glycoprotein, with analogous distri-
bution of binding registers as illustrated in Figure 4. Of
1035 Dsg1 peptides, 665 were predicted high-affinity
binders with 129 (~23%), 112 (~19%), 130 (~17%), 99
(~15%) and 43 (~6%) peptides possessing two, three,
four, five and six registers, respectively.
Redundancy Profiles of Predicted Binding Peptides
The predicted Dsg1 high-affinity binding sequences were
examined for their similarity with the Dsg3 proteome.
Each Dsg1 (15 mer) sequence was used to probe the entire
Dsg3 proteome for the highest identity Dsg3 (15 mer)
peptide with the minimal number of substitutions. Figure
5 details the degree of conservation of Dsg1 predicted
high-affinity binders with Dsg3 sequences. All predicted
Dsg1 and Dsg3 (15 mer) binding peptides share at least
four common residues along their primary sequences. It
has been reported that PV and PF autoAbs can cross-react
with Dsg1 and Dsg3 peptides with 75% identity [38].
Sequence alignment showed that 18% (or 122) of these
peptides are highly conserved with at least 75% sequence
identity. In this context, two peptides Dsg158–72
CREGEDNSKRNPIAK and Dsg159–73  REGEDNSKRNPI-
AKI near the N-terminus of ECD1 appear to be of particu-
lar interest, since they are fully conserved within the Dsg3
proteome and may represent the most likely antigenic
link between self-directed responses to two distinct
autoantigens (Dsg3 and Dsg1). A subset of patients with
PV has been shown to have T cell reactivity to both Dsg3
and Dsg1 [39]. However, defined Dsg1 epitopes have not
yet been determined.
Conclusion
Although clinical evolution of disease expression is com-
mon in PV [3,4], our understanding of how T-cells are
involved in the underlying autoreactive processes remains
poor. Collectively, the results of this study provide inter-
esting new insights into the possible mechanism of dis-
Superposition of the structures of Dsg1 and Dsg3 extracellular domains Figure 1
Superposition of the structures of Dsg1 and Dsg3 extracellular domains. Structural comparison of the Dsg1 (red) 
and Dsg3 (blue) extracellular domains. The r.m.s.d. of the entire ECD, ECD1, ECD2, ECD3, ECD4, and ECD5 are 5.56 Å, 1.03 
Å, 1.09 Å, 1.94 Å, 3.76 Å, and 6.95 Å, respectively.BMC Immunology 2008, 9:30 http://www.biomedcentral.com/1471-2172/9/30
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ease progression. Our data suggests that similar peptides
from the two known PV autoantigenic targets may bind to
DRB1*0402 and allow for intermolecular epitope spread-
ing that lead to distinct morphological categories of PV –
mucosal lesions only vs. mucocutaneous disease. None-
theless, many other factors exist, such as IgG-activated
intracellular signalling events [40], which may play a crit-
ical role in the complex disease mechanism and should
also be explored. Recently, Lucchese and coworkers [38]
discovered an immunodominant Dsg3 T-cell epitope
Dsg349–60 REWVKFAKPCRE that is highly reactive with
both PV and PF sera, with 75% identity to Dsg149–60
REWIKFAAACRE. In this context, our current approach of
epitope mapping may prove useful in facilitating the sys-
tematic discovery of peptides that cross-react with both PV
and PF autoreactive T-cells and serve as targets for poten-
tial therapeutic approaches that are efficient in both dis-
eases. Further studies are necessary to determine the
proportion of immunogenic epitopes that are capable of
stimulating autoreactive lymphocytes from both pemphi-
gus subtypes.
Molecular surface of Dsg1 and Dsg3 extracellular domains illustrating the positions of predicted DRB1*0402-specific immuno- logical (T-cell epitope) hot spots Figure 2
Molecular surface of Dsg1 and Dsg3 extracellular domains illustrating the positions of predicted DRB1*0402-
specific immunological (T-cell epitope) hot spots. Locations of predicted immunological hot spots (colored red) for 
Dsg1 and Dsg3 extracellular domains are shown in surrounding views and numbered in accordance to their extracellular 
domains.BMC Immunology 2008, 9:30 http://www.biomedcentral.com/1471-2172/9/30
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Predicted DRB1*0402-specific immunological hot spots for Dsg1 and Dsg3 glycoproteins Figure 3
Predicted DRB1*0402-specific immunological hot spots for Dsg1 and Dsg3 glycoproteins. Multiple sequence align-
ment of Dsg1 and Dsg3. Predicted hot spots (threshold = -123 kJ/mol) shaded in black, experimental Dsg3 hot spots high-
lighted red, and experimentally confirmed DRB1*0402-specific Dsg3 peptides highlighted blue. Dsg1 – Signal Peptide, SP: 1–23; 
Propeptide, PP: 24–49; Extracellular domain 1, ECD1: 50–158; ECD2: 159–270; ECD3: 271–385; ECD4: 386–497; ECD5: 498–
548; Transmembrane, TM: 549–569; Intracellular domain, ICD: 570–1049. Dsg3 – SP: 1–23; PP: 24–49; ECD1: 50–158; ECD2: 
159–268; ECD3: 269–383; ECD4: 386–499; ECD5: 500–615; TM: 616–640; ICD: 641–999.
Number of predicted binding registers for Dsg1 and Dsg3  peptides bound to DRB1*0402 Figure 4
Number of predicted binding registers for Dsg1 and 
Dsg3 peptides bound to DRB1*0402. The frequency of 
Dsg1 (colored white) and Dsg3 (colored black) peptides 
docked to DRB1*0402 shown as a function of the number of 
predicted binding registers.
Redundancy profile of predicted Dsg1 peptides to Dsg3  sequences Figure 5
Redundancy profile of predicted Dsg1 peptides to 
Dsg3 sequences. The number of predicted high-affinity 
Dsg1 (15 mer) peptide sequences shown as a function of the 
number of substitutions from the highest identity peptide 
sequence derived from the Dsg3 proteome derived using a 
15 mer sliding window.BMC Immunology 2008, 9:30 http://www.biomedcentral.com/1471-2172/9/30
Page 6 of 9
(page number not for citation purposes)
Methods
The sequence of DRB1*0402 was obtained from IMGT-
HLA database [41]. Dsg1 and Dsg3 sequence data were
obtained from Swiss-Prot [42]. To identify suitable struc-
tural templates in the Protein Data Bank (PDB) [43] for
model construction, a sequence similarity search was per-
formed using BLASTP [44] and the highest quality tem-
plates (with the best resolution, highest sequence
similarity and minimal number of missing residues) were
selected among the returned hits. The crystal structure of
DRB1*0401 (PDB code 1D5Z) was selected as template
for DRB1*0402 (97.9% identity) [33], while the solution
structures of C-cadherin (PDB code 1Q5C) and N-cad-
herin (PDB code 1NCJ) were used for constructing the
extracellular domains of both Dsg1 and Dsg3.
Model Building
The program MODELLER [45] was employed for compar-
ative modeling of DRB1*0402, Dsg1 and Dsg3. Each
model was constructed by optimally satisfying spatial
constraints obtained from the alignment of the template
structure with the target sequence and from the
CHARMM-22 force field [46], and subsequently relaxed
by conjugate gradient minimization, using the program
Internal Coordinate Mechanics (ICM) [47,48].
Peptide Docking
Overlapping 15 mer peptides are generated from the Dsg1
and Dsg3 sequences. An overlapping sliding window of
size nine is applied to each 15 mer peptide to generate all
combinations of binding registers to be modeled into the
binding groove of DRB1*0402 (Figure 6). A total of 1035
Dsg1 15 mer peptides (6210 binding registers) and 985
Dsg3 15 mer peptides (5910 binding registers) were gen-
erated and used in the current analysis. Docking was per-
formed using a standard protocol as previously described
[33-35], consisting of (i) pseudo-Brownian rigid body
docking of peptide fragments to the ends of the binding
groove, (ii) central loop closure by satisfaction of spatial
constraints, (iii) refinement of the backbone and side-
chain atoms of the core recognition residues and receptor
contact regions within 4.00 Å radius, and (iv) extension of
flanking peptide residues by satisfaction of spatial con-
straints (Figure 7).
Empirical Free Energy Functions
The scoring function presented in this study is based on
the free energy potential in ICM [47,48]. Computation of
the binding free energy was performed according to previ-
ous similar works [36,37] based on the difference between
the energy of the solvated complex and the sum of the
energy of the solvated receptor and that of the peptide lig-
and, followed by optimization using experimental IC50
values. The DRB1*0402 model optimization, training
and testing were described earlier [33].
Immunological Hotspot Prediction
In the present study, 'immunological hotspots' are
defined as antigenic regions of up to 30 amino acids based
on the sum of predicted binding energies of the top four
binders within a window of 30 amino acids [49,50].
Where available, predicted hotspots were validated using
available experimentally determined sites (Figure 3).
Generation of Dsg1 and Dsg3 peptide sequences for docking into DRB1*0402 Figure 6
Generation of Dsg1 and Dsg3 peptide sequences for docking into DRB1*0402. Overlapping 15 mer peptides are 
generated from the Dsg1 and Dsg3 sequences. For each 15 mer peptide, an overlapping sliding window of size nine is applied 
to generate all combinations of binding registers to be modeled into the binding groove of DRB1*0402.BMC Immunology 2008, 9:30 http://www.biomedcentral.com/1471-2172/9/30
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Flowchart of the four-step docking procedure used in this work Figure 7
Flowchart of the four-step docking procedure used in this work. Peptides are docked into DRB1*0402 using a four-
step procedure consisting of: (i) pseudo-Brownian rigid body docking of peptide fragments to the ends of the binding groove, 
(ii) central loop closure by satisfaction of spatial constraints, (iii) refinement of the backbone and side-chain atoms of the core 
recognition residues and receptor contact regions and (iv) extension of flanking peptide residues by satisfaction of spatial con-
straints.BMC Immunology 2008, 9:30 http://www.biomedcentral.com/1471-2172/9/30
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Accessible Surface Areas
Solvent accessible surface areas were calculated with the
program NACCESS [51] by tracing out the maximum per-
mitted van der Waals' contact that is covered by the center
of a water molecule (1.40 Å probe radius) as it rolls over
the surface of the protein.
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